Innova Wealth Partners Trims Stake in GSK plc (NYSE:GSK)

Innova Wealth Partners lessened its stake in shares of GSK plc (NYSE:GSKFree Report) by 8.5% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 10,774 shares of the pharmaceutical company’s stock after selling 1,000 shares during the period. Innova Wealth Partners’ holdings in GSK were worth $399,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in GSK. Versant Capital Management Inc lifted its position in shares of GSK by 2,816.7% in the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock valued at $26,000 after acquiring an additional 676 shares in the last quarter. Larson Financial Group LLC boosted its position in shares of GSK by 271.8% during the third quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 647 shares during the last quarter. BKM Wealth Management LLC bought a new stake in GSK in the 4th quarter valued at $32,000. Jones Financial Companies Lllp lifted its stake in GSK by 62.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock worth $48,000 after purchasing an additional 509 shares in the last quarter. Finally, Princeton Global Asset Management LLC increased its holdings in shares of GSK by 54.3% in the fourth quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company’s stock worth $56,000 after purchasing an additional 533 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Trading Up 0.4 %

GSK stock traded up $0.17 during mid-day trading on Wednesday, hitting $45.83. The company’s stock had a trading volume of 2,180,014 shares, compared to its average volume of 3,469,532. GSK plc has a one year low of $33.33 and a one year high of $45.93. The stock has a market cap of $94.98 billion, a PE ratio of 16.62, a P/E/G ratio of 1.94 and a beta of 0.65. The company has a 50 day moving average of $42.20 and a 200-day moving average of $39.62. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.58 and a current ratio of 0.87.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be paid a dividend of $0.3762 per share. This is a boost from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 dividend on an annualized basis and a dividend yield of 3.28%. The ex-dividend date of this dividend is Thursday, May 16th. GSK’s dividend payout ratio is 57.61%.

Wall Street Analyst Weigh In

GSK has been the topic of a number of recent research reports. Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 13th. Morgan Stanley initiated coverage on GSK in a research note on Tuesday, January 23rd. They set an “equal weight” rating on the stock. Finally, Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Check Out Our Latest Stock Analysis on GSK

About GSK

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Read More

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.